Hear Talk Audio
Post-Transplant Outcomes in High Risk Multiple Myeloma
Treatment of patients with myeloma has changed dramatically in the past years due to development of new agents and myeloma specific targets. Despite these advancements, long term benefits remains less clear in high-risk multiple myeloma patients. Myeloma is classified as high-risk based on presence of cytogenetic abnormalities and poor treatment outcomes. We are talking to Dr. Parameswaran Hari on his recent research on post-transplant outcomes in high risk myeloma patients.